Mizuho Securities analyst Difei Yang downgraded Viveve Medical Inc (VIVE) to Sell on July 23 and set a price target of $0.20. The company’s shares closed yesterday at $0.17, close to its 52-week low of $0.14.
According to TipRanks.com, Yang is a 4-star analyst with an average return of 8.4% and a 42.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.
Viveve Medical Inc has an analyst consensus of Moderate Buy, with a price target consensus of $2.50.
See today’s analyst top recommended stocks >>
Based on Viveve Medical Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.03 million. In comparison, last year the company had a GAAP net loss of $11.52 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.
